Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPS-2071 Phase 2 trial in IBS-D
ChiCTR2600129705Phase 2Completed
- Sponsor
- Union Hospital
- Start
- Aug 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of OPS-2071 in Diarrhea-predominant irritable bowel syndrome (IBS-D) (4 arms), sponsored by Union Hospital. Primary endpoints: Abdominal pain intensity and Stool type (consistency). Started Aug 2026; status: completed.
02
Drugs
OPS-2071
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on ChiCTR2600129705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129705.